Abstracts tagged "Biologic drugs"

Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRÃ¡
Iain B. McInnes¹, Gerd Burmester², Joel M. Kremer³, Pedro Miranda⁴, Mariusz Korkosz⁵, Jiri Vencovsky⁶, Andrea Rubbert-Roth⁷, Eduardo Mysler⁸, David Close⁹, Matthew A. Sleeman¹⁰, Alex Godwood¹¹, Sara Sandbach¹², Patricia C. Ryan¹³, Dominic Sinibaldi¹⁴, Wendy White¹³, Nadine A. Defranoux¹⁵ and Michael Weinblatt¹⁶, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁴Centro de Estudios Reumatologicos, Santiago, Chile, ⁵Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, ⁶Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, ⁷Med Clinic I, University of Cologne, koln, Germany, ⁸Rheumatology, OMI, Buenos Aires, Argentina, ⁹Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ¹⁰Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ¹¹Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ¹²Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, ¹³Translational Sciences, MedImmune, Gaithersburg, MD, ¹⁴R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, ¹⁵Crescendo Bioscience Inc., South San Francisco, CA, ¹⁶Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
Abstract Number: 2482 • 2014 ACR/ARHP Annual Meeting
Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis
Antonio Gómez-Centeno¹, Olga Martínez², Francisco Javier Ballina³, José Manuel Rodríguez⁴, Jenaro Graña⁵, Manuel Brito⁶, Juana Sampedro⁷, Gerardo Iglesias⁸, Concepción Delgado⁹ and Indalecio Monteagudo¹⁰, ¹Hospital Parc Taulí, Sabadell, Spain, ²Hospital Virgen de la Concha, Zamora, Spain, ³Hospital Central de Asturias, Oviedo, Spain, ⁴Hospital Getafe, Getafe, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Nuestra Señora Candelaria, Santa Cruz de Tenerife, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸Complejo Hospitalario Palencia, Palencia, Spain, ⁹Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁰Hospital Gregorio Marañón, Madrid, Spain
Background/Purpose The treatment for Rheumatoid Arthritis (RA) is based on synthetic or biological disease-modifying drugs (DMARDs). Current guidelines recommend biologics in combination with methotrexate as…
Abstract Number: 1432 • 2014 ACR/ARHP Annual Meeting
Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment
Umut Kalyoncu¹, Abdulsamet Erden², Hakan Babaoglu³, Murat Torgutalp³, Sadettin Kilickap⁴, Omer Karadag⁵, Sule Apras Bilgen⁵, Ihsan Ertenli¹, Ali Akdogan⁵ and Sedat Kiraz⁵, ¹Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ²Rheumatology,Hacettepe University Faculty of Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁴Preventive Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment: HUR-BIO real life results.Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, which, in many patients, leads…
Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José M. Senabre-Gallego¹, José Rosas-Gómez de Salazar¹, Esteban Salas-Heredia¹, Gregorio Santos-Soler¹, Francisca Llinares-Tello², Carlos Santos-Ramirez³, Mabel Sánchez-Barrioluengo⁴, Xavier Barber-Vallés⁵, Rafaela Ortega³, Ana Pons¹, Catalina Cano¹ and Maria Luisa Lorente-Betoret¹, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Salud, Denia, Spain, ⁴Ingenio (CSIC-UPV), Universitat Politècnica de València, Valencia, Spain, ⁵Center of Operations Research, University Miguel Hernández, Elche, Spain
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…
Abstract Number: 1251 • 2014 ACR/ARHP Annual Meeting
Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases
Montserrat Santos-Gómez¹, Victor Llorens², Marina Mesquida², Ricardo Blanco¹, Vanesa Calvo-Río¹, Olga Maíz³, Ana Blanco⁴, Maite Sainz de la Maza², Alfredo Adan², Leyre Riancho-Zarrabeitia¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ⁴Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain
Background/Purpose Anti-TNF-α therapy may be useful in cases of uveitis refractory to standard synthetic immunosuppressive drugs. Infliximab (IFX) and adalimumab (ADA) are the biologic agents…
Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting
Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom
Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…
Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting
Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)
Polina Putrik¹, Sofia Ramiro², Elisabeth Lie³, Andras Keszei⁴, Desirée van der Heijde⁵, Robert Landewé⁶, Tore K. Kvien⁷, Till Uhlig⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁷Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…
Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 1144 • 2014 ACR/ARHP Annual Meeting
Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis
Nick Bansback¹, Diane V. Lacaille², Daphne Guh³, Kamran Shojania⁴ and Aslam H. Anis³, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Recent randomized controlled trials in rheumatoid arthritis (RA) patients have determined that a strategy of first adding the two Disease Modifying Anti-Rheumatic Drugs (DMARDs)…
Abstract Number: 2202 • 2014 ACR/ARHP Annual Meeting
Pilot Study of Tocilizumab in Patients with Erdheim-Chester Disease
Giulio Cavalli¹, Alvise Berti¹, Barbara Gulgielmi¹, Marco Gelpi², Riccardo Biavasco², Corrado Campochiaro¹, Alessandro Tomelleri², Marina Ferrarini³, Maria Grazia Sabbadini² and Lorenzo Dagna², ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Department of Oncology, San Raffaele Scientific Institute, MIlan, Italy
Background/Purpose Erdheim-Chester disease (ECD) is a rare, systemic disorder of unknown etiology, characterized by tissue infiltration with CD68+, CD1a- foamy histiocytes. ECD is a chronic,…
Abstract Number: 1001 • 2014 ACR/ARHP Annual Meeting
Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1
Satoshi Yamasaki and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient…
Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT
Koichi Okamura¹, Yukio Yonemoto¹, Chisa Okura² and Kenji Takagishi¹, ¹Orthopaedic Surgery, Gunma University, Maebashi, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…
Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Till Uhlig¹, Vibeke Norvang², Elisabeth Lie¹, Erik Rødevand³, Knut Mikkelsen⁴, Åse S. Lexberg⁵, Synøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁴Revmatismesykehuset, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁶Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…
Abstract Number: 2123 • 2014 ACR/ARHP Annual Meeting
Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
Chris Tonner¹, Gabriela Schmajuk² and Jinoos Yazdany², ¹3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs). Coverage for…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].